06 deCode Genetics

Participant's Lead

Project Staff

Partner Presentation

deCODE has developed DNA-based reference laboratory tests for assessing the genetic contribution to individual risk of common diseases and by providing such testing services deCODE enables healthcare providers to bring that information together with the assessment of standard risk factors in clinical practice. Using its unique expertise and population resources, deCODE has discovered key genetic risk factors for common diseases, including common SNPs, rare SNPs and rare CNVs. deCODE has uncovered structural polymorphisms associated with disorders, developed novel approaches such as long range phasing and tests for estimating effects of parental origin of susceptibility variants. deCODE is whole genome sequencing 2,500 Icelandic subjects and is continuously imputing the data into a set of around 100,000 chip typed subjects in which association with ASD can be tested. deCODE has associated several CNVs with psychiatric disorders, including ASD. deCODE?s leadership in genetics ensures that subjects carrying high-risk variants can be recruited for fMRI analysis and neuropsychological phenotyping. deCODE carries out its studies in Reykjavik, Iceland in its CLIA certified laboratory of 150,000 square feet, housing 153 employees and large research infrastructures, enabling high throughput genotyping and data handling and analysis. The company?s genotyping and whole genome sequencing capacity is now one of the highest in the world. deCODE has a large population-based biobank containing whole blood and DNA samples with extensive relevant phenotypic information from around 120,000 Icelanders.